Comments
Pharma major Venus Remedies has received marketing authorisations for three variants of Docetaxel in Israel and Cytarabjne 100MG in Colombia.
According to the company’s regulatory filing, the approved Docetaxel variants are 160MG/8ML, 80MG/4ML, 20MG/1ML.
The Venus Remedies stock surged by 7.15 per cent on the NSE, at ₹403.30, as of 1:31 pm on Thursday.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.